KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,491,640 | +22.9% | 373,721 | -0.4% | 0.00% | 0.0% |
| Q2 2023 | $5,281,852 | +30.1% | 375,109 | -0.6% | 0.00% | +100.0% |
| Q1 2023 | $4,059,236 | +68887.7% | 377,258 | -4.0% | 0.00% | -50.0% |
| Q4 2022 | $5,884 | -99.9% | 392,791 | -0.2% | 0.00% | 0.0% |
| Q3 2022 | $5,052,000 | +28.0% | 393,466 | -3.4% | 0.00% | +100.0% |
| Q2 2022 | $3,946,000 | +10.0% | 407,147 | +12.8% | 0.00% | 0.0% |
| Q1 2022 | $3,588,000 | +91.4% | 360,940 | +126.6% | 0.00% | 0.0% |
| Q4 2021 | $1,875,000 | +22.5% | 159,318 | +18.6% | 0.00% | – |
| Q3 2021 | $1,530,000 | -66.5% | 134,287 | -59.1% | 0.00% | -100.0% |
| Q2 2021 | $4,572,000 | +3.8% | 328,214 | +37.9% | 0.00% | 0.0% |
| Q1 2021 | $4,406,000 | +233.0% | 238,047 | +218.0% | 0.00% | – |
| Q4 2020 | $1,323,000 | +23.0% | 74,856 | +6.6% | 0.00% | – |
| Q3 2020 | $1,076,000 | -35.1% | 70,247 | +7.9% | 0.00% | -100.0% |
| Q2 2020 | $1,659,000 | +63.3% | 65,080 | -1.2% | 0.00% | 0.0% |
| Q1 2020 | $1,016,000 | +244.4% | 65,871 | +146.8% | 0.00% | – |
| Q4 2019 | $295,000 | – | 26,690 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
| Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
| Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
| AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
| Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
| RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
| ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
| Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |